Cell therapy harnesses the body's immune system to treat diseases, primarily focusing on cancer and genetic disorders. Companies in this sector deliver innovative therapies, often involving cellular engineering, that improve patient outcomes by targeting and eliminating diseased cells. The industry is rapidly evolving, with advancements in technology leading to more effective and accessible therapies. Insights into emerging trends, such as regenerative medicine and personalized treatments, reveal a collaborative environment among biotech firms, research institutions, and medical centers, all aiming to push the boundaries of medical science and address significant health challenges.

The list features a varied array of companies, ranging in size from small startups to larger established firms. With headquarters spread across the United States, China, South Korea, and Europe, these companies have been founded between 1992 and 2024. They specialize in cell and gene therapy developments aimed at treating various cancers and autoimmune diseases. The notable mix showcases a blend of public and private equity ownership, emphasizing the attractiveness of this sector for investment and growth opportunities.

Continue reading to discover the top cell therapy companies.

Top 24 Cell Therapy Companies

1. Kite Pharma

• Website: kitepharma.com
• Ownership type: Corporate
• Headquarters: Santa Monica, California, United States (USA)
• Employee distribution: United States (USA) 65%, Netherlands 28%, United Kingdom (UK) 2%, Other 5%
• Latest funding: $11.9B, August 2017
• Founded year: 2009
• Headcount: 1001-5000
• LinkedIn: kite-pharma-inc-

Kite Pharma, Inc., founded in 2009 and based in Santa Monica, California, is a biotechnology company dedicated to advancing cancer treatment through innovative immunotherapy products, particularly CAR T-cell therapies. The company focuses on utilizing the immune system to target and eliminate cancer cells, primarily in blood cancers. Kite has established a robust pipeline that includes investigational therapies and next-generation technologies aimed at improving patient outcomes. Their commitment to research and development is complemented by a strong manufacturing network, ensuring that their therapies are accessible to patients in need. Kite's acquisition by Gilead Sciences in 2017 has further enhanced its capabilities, allowing it to leverage Gilead's resources while maintaining its focus on cell therapy. Kite's therapies, such as YESCARTA® and TECARTUS®, have made significant strides in treating various hematological malignancies, showcasing their dedication to transforming cancer care.

2. Dendreon

• Website: dendreon.com
• Ownership type: Corporate
• Headquarters: Seal Beach, California, United States (USA)
• Employee distribution: United States (USA) 97%, Other 3%
• Latest funding: $819.9M, June 2017
• Founded year: 1992
• Headcount: 501-1000
• LinkedIn: dendreon

Dendreon Pharmaceuticals LLC, based in Seal Beach, California, is a biotechnology company focused on immunotherapy for cancer treatment. Founded in 1992, Dendreon is known for its flagship product, Provenge (sipuleucel-T), which is the first FDA-approved treatment for advanced prostate cancer that harnesses the power of the patient's own immune cells. Since its approval in 2010, Provenge has been prescribed to nearly 40,000 men, demonstrating its impact on patient outcomes. In addition to its therapeutic offerings, Dendreon provides cellular therapy manufacturing services, assisting other companies in bringing innovative cancer therapies to market. With a workforce of around 610 employees, Dendreon is actively engaged in research and development, clinical trials, and the commercialization of cellular therapies, positioning itself as a significant player in the biotechnology sector.

3. Juventas Cell Therapy Corp.

• Website: juventas.cn
• Ownership type: Private Equity
• Headquarters: Tianjin, Tianjin, China
• Employee distribution: China 100%
• Latest funding: Series C, $63.3M, July 2021
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: %e5%90%88%e6%ba%90%e7%94%9f%e7%89%a9%e7%a7%91%e6%8a%80-%e5%a4%a9%e6%b4%a5-%e6%9c%89%e9%99%90%e5%85%ac%e5%8f%b8

Juventas Cell Therapy Corp., also known as 合源生物科技（天津）有限公司, is a biopharmaceutical company based in Tianjin, China, specializing in cell and gene therapy. Founded in 2018, the company has rapidly developed a strong focus on CAR-T cell therapies, particularly for blood cancers and autoimmune diseases. Juventas has established a robust research and development pipeline, with over ten products in various stages of development. Their flagship product, CNCT19, is notable for being the first CAR-T therapy approved in China for treating relapsed or refractory B-cell acute lymphoblastic leukemia. The company has also secured significant funding, with a Series C round raising approximately $63 million in July 2021, which underscores investor confidence in their innovative approach and growth potential. By collaborating with leading medical institutions, Juventas aims to ensure that their therapies are accessible to patients in need, reflecting their commitment to addressing critical healthcare challenges.

4. BlueRock Therapeutics

• Website: bluerocktx.com
• Ownership type: Venture Capital
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: Canada 51%, United States (USA) 48%
• Latest funding: $1.0B, August 2019
• Founded year: 2016
• Headcount: 201-500
• LinkedIn: bluerocktx

BlueRock Therapeutics LP is a biotechnology firm based in Cambridge, Massachusetts, founded in 2016. The company is dedicated to developing innovative cell therapies aimed at treating degenerative diseases. Their primary focus is on conditions such as Parkinson's disease and inherited retinal diseases, where they aim to restore lost functions through advanced regenerative medicine. BlueRock utilizes pluripotent stem cells, particularly induced pluripotent stem cells (iPSCs), to create specific cell types that can replace those damaged or lost due to disease. The company has made significant strides in its clinical programs, including the investigational therapy bemdaneprocel for Parkinson's disease, which has shown promising results in clinical trials. BlueRock Therapeutics is a wholly-owned subsidiary of Bayer AG, which supports its mission to transform the treatment of degenerative diseases through cell therapy. The company has raised substantial funding, with a reported last funding amount of $1 billion in 2019, underscoring its potential and ambition in the biotechnology sector.

5. Curocell

• Website: curocellbtx.com
• Ownership type: Private Equity
• Headquarters: Daejeon, Daejeon, South Korea
• Employee distribution: South Korea 100%
• Latest funding: $30.1M, January 2022
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: curocell

Curocell, established in 2016 and based in Daejeon, South Korea, is a biotechnology firm dedicated to advancing CAR-T cell therapy and related technologies. The company is focused on developing innovative cancer treatments and collaborates with various hospitals and medical institutions to provide advanced therapeutic options. Curocell's proprietary OVIS™ platform technology is designed to enhance CAR-T therapy by preventing immune cell exhaustion, a common limitation in traditional CAR-T approaches. The company has made significant strides in the industry, including securing clinical contracts with prominent medical institutions for leukemia and lymphoma treatments. In January 2022, Curocell raised approximately $30 million in funding, reflecting strong investor confidence in their potential to impact cancer therapy.

6. Miltenyi Biomedicine

• Website: miltenyibiomedicine.com
• Ownership type: Private
• Headquarters: Bergisch Gladbach, North Rhine-Westphalia, Germany
• Employee distribution: Germany 81%, United States (USA) 13%, Other 6%
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: miltenyi-biomedicine

Miltenyi Biomedicine, founded in 2019 and based in Bergisch Gladbach, Germany, is a biopharmaceutical company dedicated to the development of innovative cell and gene therapies aimed at treating serious diseases. The company is particularly focused on personalized treatments for cancer and regenerative therapies, striving to enhance patient outcomes. Their operations include extensive research, development, and manufacturing of therapeutic products, with a strong emphasis on addressing difficult-to-treat hematological cancers through CAR T technology. Miltenyi Biomedicine is committed to providing evidence-based medicine and ensuring that their therapeutic approaches are grounded in real-world data. They are also exploring treatments for other serious conditions, such as Alzheimer’s and Parkinson’s diseases. The company operates under strict regulatory compliance, with facilities inspected by authorities like the FDA, ensuring high standards in their manufacturing processes. Their clinical pipeline includes investigational therapies currently undergoing pivotal trials, reflecting their active role in advancing cell therapy solutions.

7. AvenCell

• Website: avencell.com
• Ownership type: Private Equity
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: Germany 56%, United States (USA) 41%, France 3%
• Latest funding: Series B, $112.0M, October 2024
• Founded year: 2021
• Headcount: 51-200
• LinkedIn: avencell

AvenCell Therapeutics, Inc., founded in 2021 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies for challenging cancers. The company specializes in CAR-T cell therapies, utilizing proprietary technologies such as the Universal Switchable CAR and an allogeneic platform. These innovations are designed to enhance the safety and effectiveness of treatments, particularly for solid tumors and other hard-to-treat cancers. AvenCell has attracted substantial investment, including $112 million in a Series B funding round in October 2024, reflecting strong backing from notable investors like Blackstone Life Sciences. With a focus on patient-centric solutions and a robust pipeline, AvenCell is positioned to make significant contributions to the field of cell therapy.

8. Beike Biotechnology Co., Ltd.

• Website: beikebiotech.com
• Ownership type: Private
• Headquarters: Shenzhen, Guangdong, China
• Employee distribution: China 72%, Thailand 28%
• Latest funding: January 2015
• Founded year: 2005
• Headcount: 201-500
• LinkedIn: beike-biotechnology

Beike Biotechnology Co., Ltd. is a private biotechnology firm based in Shenzhen, Guangdong, China, founded in 2005. The company specializes in stem cell research and therapies, particularly focusing on the clinical application of adult stem cells and immunotherapy. Beike has developed a range of innovative treatments aimed at chronic illnesses, collaborating with hospitals and research institutions to advance the field of regenerative medicine. With over 20,000 patients treated, Beike operates more than 25 laboratories dedicated to research and cell processing, ensuring high safety and quality standards. The company has a strong research team, including scientists from prestigious universities, and has published numerous peer-reviewed papers. Beike's commitment to quality is reflected in their adherence to strict manufacturing standards and their accreditation by international organizations. They actively seek partnerships to enhance their research capabilities and expand their treatment offerings.

9. ImmunoACT

• Website: immunoact.com
• Ownership type: Private
• Headquarters: Navi Mumbai, Maharashtra, India
• Employee distribution: India 100%
• Latest funding: $484,000, May 2023
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: immunoact

ImmunoACT, founded in 2018 and based in Navi Mumbai, Maharashtra, is a private biotechnology firm focused on cell and gene therapies, with a particular emphasis on CAR-T cell therapies. As India's first indigenous CAR-T cell therapy company, ImmunoACT aims to provide innovative and affordable treatment options for cancer patients, addressing critical gaps in current cancer care. Their flagship product, NexCAR19, represents a significant advancement in the field, designed to enhance the effectiveness of T-cells in targeting specific cancers while minimizing side effects. The company operates a fully integrated model that spans research, development, and commercialization, ensuring that they can bring their therapies from the lab to the clinic efficiently. With a dedicated team and partnerships with prestigious institutions like IIT Bombay and Tata Memorial Centre, ImmunoACT is positioned to make a meaningful impact in the oncology landscape. The company secured funding of approximately $483,869 in May 2023, reflecting continued investor confidence in their mission and capabilities.

10. Interius BioTherapeutics

• Website: interiusbio.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $51.4M, June 2024
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: interius-biotherapeutics

Interius BioTherapeutics is a biotechnology firm based in Philadelphia, Pennsylvania, founded in 2019. The company specializes in developing innovative gene therapies, particularly focusing on in vivo cell-specific gene delivery technologies. Their primary aim is to create CAR T cells for treating hematologic malignancies, which are cancers that affect blood cells. Interius operates in the biotechnology and healthcare sectors, catering to patients and healthcare providers seeking advanced treatment options. The company has recently raised over $51 million in a Series B funding round, which underscores investor confidence in their approach. Interius is currently preparing to commence a Phase 1 clinical trial for its lead product, INT2104, which targets B cell malignancies. This investigational therapy represents a shift from traditional methods by allowing for the generation of CAR T cells directly within the patient's body, eliminating the need for pre-conditioning chemotherapy. Their innovative platform has the potential to address unmet medical needs in oncology and beyond, making them a noteworthy entity in the cell therapy space.

11. Inceptor Bio

• Website: inceptor.bio
• Ownership type: Corporate
• Headquarters: Morrisville, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $21.0M, February 2025
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: inceptor-bio

Inceptor Bio, founded in 2020 and based in Morrisville, North Carolina, is a biotechnology company dedicated to developing advanced cell therapies for cancer treatment. The company specializes in innovative solutions such as the OUTLAST™ CAR T platform and CAR-M therapies, which aim to tackle the complexities associated with solid tumors. Inceptor Bio's primary customers include healthcare providers and research institutions seeking effective cancer therapies. Recently, the company raised $21 million in Series A funding, which underscores its potential for growth and development in the competitive biotech landscape. Inceptor Bio is actively involved in the industry, presenting its research at major conferences and collaborating with other organizations to enhance the efficacy of its therapies.

12. MedTherapy Biotech

• Website: medtherapybiotech.com
• Ownership type: Private
• Headquarters: Quincy, Massachusetts, United States (USA)
• Employee distribution: India 76%, United States (USA) 24%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: medtherapy

MedTherapy Biotech, based in Quincy, Massachusetts, is a biotechnology company that specializes in cancer cell and gene therapies. Founded in 2018, the company was established by a team of experts from Harvard University and former executives from Novartis. MedTherapy operates as a Contract Development and Manufacturing Organization (CDMO), providing a full spectrum of services that include the manufacturing of CAR-T cell therapies and viral vectors, as well as regulatory and analytical support. Their facilities are strategically located in Boston, USA, and New Delhi, India, allowing them to cater to a global clientele. MedTherapy's mission is to make cancer gene therapy more affordable and accessible, addressing the significant challenges of high costs and complex manufacturing processes that have historically limited patient access to these advanced treatments. The company is committed to innovation, having developed proprietary technologies that significantly reduce manufacturing time and costs, thereby enhancing the scalability of their services. Their clientele includes pharmaceutical companies and research institutions that require advanced therapeutic solutions, underscoring their relevance in the biotechnology sector.

13. Ferring Ventures Oy

• Website: kct.fi
• Ownership type: Private
• Headquarters: Kuopio, North Savo, Finland
• Employee distribution: Finland 100%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: kuopio-center-for-gene-and-cell-therapy-kct

Ferring Ventures Oy, founded in 2018 and based in Kuopio, Finland, is a biotechnology firm dedicated to the research and development of advanced therapy medicinal products (ATMPs), particularly in the area of cell therapy. The company engages in high-level research aimed at creating innovative therapies for cancer patients. They work closely with academic institutions and contract research organizations to advance their projects through various phases of clinical trials. Ferring Ventures Oy emphasizes the importance of robust research methodologies and has developed capabilities in cell characterization and product development. Their commitment to translating research into practical applications is evident in their ongoing collaborations, such as with the University of Eastern Finland, which focuses on enhancing cell therapy solutions. This collaborative approach not only strengthens their research output but also positions them as a key contributor to advancements in cell therapy.

14. Orca Bio

• Website: orcabio.com
• Ownership type: Venture Capital
• Headquarters: Menlo Park, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series D, $192.0M, June 2020
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: orcabio

Orca Bio, founded in 2016 and based in Menlo Park, California, is a biotechnology firm dedicated to developing high-precision cell therapies for patients suffering from serious blood disorders. The company emerged from research conducted in the lab of Dr. Irv Weissman at Stanford University, aiming to address the limitations and risks associated with traditional transplant methods. Orca Bio's primary investigational therapies, Orca-T and Orca-Q, target blood cancers and related conditions, with a focus on improving survival rates and reducing complications like graft-versus-host disease (GvHD). The company has made notable progress in clinical trials, including a Phase III study for Orca-T, and has presented positive data at significant medical conferences. With a workforce of around 184 employees and substantial venture capital backing, Orca Bio is positioned as a relevant player in the cell therapy sector.

15. Wugen

• Website: wugen.com
• Ownership type: Private Equity
• Headquarters: St. Louis, Missouri, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $172.0M, July 2021
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: wugen

Wugen is a clinical-stage biotechnology company based in St. Louis, Missouri, founded in 2018. The company specializes in developing cellular therapies for cancer, focusing on off-the-shelf NK (natural killer) and CAR-T (chimeric antigen receptor T-cell) therapies. These therapies are designed to address the needs of patients suffering from solid tumors and hematologic malignancies. Wugen operates through a comprehensive approach that includes research and development, manufacturing, and clinical trials. The company has made significant progress in its pipeline, with investigational therapies like WU-CART-007 and WU-NK-101 showing promising results in clinical settings. Wugen has also secured substantial funding, with a Series B round raising $172 million in July 2021, which supports its ongoing research and development efforts. Their commitment to advancing cancer treatment through innovative cellular therapies positions them as a relevant player in the biotechnology industry.

16. Carina Biotech

• Website: carinabiotech.com
• Ownership type: Venture Capital
• Headquarters: Adelaide, South Australia, Australia
• Employee distribution: Australia 100%
• Latest funding: $7.5M, August 2023
• Founded year: 2016
• Headcount: 1-10
• LinkedIn: carina-biotech

Carina Biotech, founded in 2016 and based in Adelaide, South Australia, is a biotechnology firm dedicated to the research and development of CAR-T therapies aimed at treating solid tumors. The company leverages the patient's immune system to combat cancer, focusing on innovative approaches that enhance treatment efficacy. Carina Biotech operates through clinical trials and utilizes proprietary technology platforms to advance its therapies. Their notable LGR5 CAR-T program targets advanced colorectal cancer, showcasing their commitment to addressing challenging cancer types. In August 2023, Carina Biotech secured $7.5 million in funding, reflecting confidence from investors in their potential to deliver impactful cancer treatments. The company collaborates with various research leaders and medical advisors, further strengthening its position in the biotechnology sector.

17. Ensoma

• Website: ensoma.com
• Ownership type: Private Equity
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 97%, Denmark 3%
• Latest funding: Series B, $50.0M, May 2023
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: ensomabio

Ensoma is a biotechnology firm based in Boston, Massachusetts, founded in 2019. The company is dedicated to developing innovative medical treatments through its proprietary Engenious™ platform. This platform enables the creation of one-time in vivo therapies that can precisely engineer immune cells to address various diseases, including cancer and autoimmune disorders. Ensoma's approach is notable for its potential to provide curative therapies by modifying immune cells directly within the body. The company has garnered significant attention in the industry, evidenced by its recent Series B funding round, which raised $85 million to further its mission. With a focus on pioneering new therapeutic solutions, Ensoma is positioned as a relevant player in the cell therapy sector, catering to healthcare providers and organizations seeking advanced treatment options.

18. PsiOxus

• Website: psioxus.com
• Ownership type: Private Equity
• Headquarters: Abingdon, England, United Kingdom (UK)
• Latest funding: $31.8M, May 2015
• Founded year: 2010
• Headcount: 51-200
• LinkedIn: psioxus

PsiOxus, also known as Akamis Bio, is a biotechnology company based in Abingdon, England, founded in 2010. The company specializes in tumor gene therapy, focusing on the development of Tumor-Specific Immuno-Gene (T-SIGn®) therapeutics. These innovative treatments are designed to enhance the immune system's ability to recognize and attack solid tumors. PsiOxus operates in the oncology sector, conducting research and clinical trials to advance their therapeutic pipeline. Their lead program, NG-350A, is currently in Phase 1b clinical trials, demonstrating their commitment to bringing new cancer treatments to market. The company has received significant funding, amounting to $31.75 million, which underscores investor confidence in their approach and technology. PsiOxus collaborates with various partners in the immuno-oncology field, aiming to maximize the potential of their T-SIGn® platform and improve treatment outcomes for patients with difficult-to-treat cancers.

19. CytoImmune Therapeutics

• Website: cytoimmune.com
• Ownership type: Private
• Headquarters: Monrovia, California, United States (USA)
• Employee distribution: Puerto Rico 80%, United States (USA) 20%
• Latest funding: $100.3M, August 2021
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: cytoimmune-therapeutics

CytoImmune Therapeutics is a biotechnology firm based in Monrovia, California, founded in 2019. The company is dedicated to developing innovative cell therapy solutions, particularly focusing on CAR NK cell therapies aimed at treating various forms of cancer. With a clinical GMP manufacturing facility located in Toa Baja, Puerto Rico, CytoImmune is equipped to produce high-quality cell therapies. Their approach leverages proprietary technologies to engineer NK cells, allowing for off-the-shelf therapies that do not require HLA matching. This positions them uniquely in the market, as they aim to address both solid tumors and hematologic malignancies. The company has received significant funding, amounting to over $100 million, which underscores its potential and the interest it has garnered from investors. CytoImmune's commitment to advancing cancer treatment through cell therapy makes it a notable player in the biotechnology sector.

20. Appia Bio

• Website: appiabio.com
• Ownership type: Venture Capital
• Headquarters: Los Angeles, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $52.0M, May 2021
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: appiabio

Appia Bio is a biotechnology firm based in Los Angeles, California, founded in 2020. The company is dedicated to discovering and developing next-generation allogeneic cell therapies aimed at treating cancer. Their mission is to create novel, curative, and accessible therapies for patients, particularly those battling hematologic and solid tumors. Appia Bio's innovative approach is centered around their proprietary ACUA platform, which leverages the unique properties of NKT cells to address challenges in cancer treatment. The company has attracted significant investment, securing $52 million in a Series A funding round in May 2021. This financial backing supports their ambitious pipeline, which includes therapies targeting multiple myeloma and solid tumors. With a team of experienced professionals and a strong scientific advisory board, Appia Bio is poised to make a notable impact in the field of cell therapy.

21. TCRCure Biopharma Corp.

• Website: en.tcrcure.com
• Ownership type: Private
• Headquarters: Guangzhou, Guangdong, China
• Employee distribution: United States (USA) 67%, China 33%
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: tcrcure-biopharma-corp

TCRCure Biopharma Corp. is a biopharmaceutical company based in Guangzhou, China, with additional operations in the United States. Founded in 2016, TCRCure focuses on developing innovative cancer immunotherapies, particularly through engineered T cell therapies. The company operates research and development centers and manufacturing facilities that adhere to current Good Manufacturing Practices (cGMP). TCRCure is dedicated to advancing tumor immunotherapy technologies and has made significant strides in clinical trials for various solid tumors. Their proprietary platforms, such as ASPIRE and TRUST, are designed to improve T cell recognition and enhance the safety of traditional therapies. TCRCure has also received regulatory approval for its clinical studies, indicating its active role in the industry and commitment to bringing new treatments to market.

22. BioSyngen

• Website: biosyngen.com
• Ownership type: Venture Capital
• Headquarters: Singapore, Singapore
• Employee distribution: Singapore 87%, China 13%
• Latest funding: $78.2M, October 2021
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: biosyngen

BioSyngen, founded in 2016 and based in Singapore, is a biotechnology firm focused on developing innovative cell and gene therapies for cancer treatment. The company aims to tackle unmet needs in oncology through advanced immunotherapies, specifically targeting solid tumors, which represent over 90% of new cancer cases globally. BioSyngen's operations include research and development, manufacturing, and collaboration with healthcare providers to enhance patient outcomes. They have a pipeline featuring multiple first-in-class products, including CAR-T, TCR-T, and TIL therapies, which are currently in various stages of clinical trials. The company has secured significant funding, amounting to approximately $78 million, which underscores its potential for growth and innovation in the cell therapy sector. BioSyngen's commitment to addressing critical challenges in cancer treatment positions it as a noteworthy player in the biotechnology industry.

23. Leucid Bio

• Website: leucid.com
• Ownership type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 100%
• Latest funding: Series A, $15.9M, October 2021
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: leucid-bio-ltd

Leucid Bio is a clinical-stage biotechnology firm based in London, UK, founded in 2014. The company specializes in the development of next-generation CAR-T cell therapies aimed at treating refractory cancers. Their innovative approach is centered around the proprietary Lateral CAR platform, which is designed to improve the efficacy and safety of CAR-T therapies. Leucid Bio has a strong focus on solid tumors, an area where traditional CAR-T therapies have struggled. They have developed a lead asset, LEU011, which targets NKG2D ligands and is currently in pre-clinical development. The company has also made advancements in manufacturing processes, allowing for more efficient and scalable production of CAR-T cells. Leucid Bio has raised approximately £15 million in funding, with their latest Series A round completed in October 2021, indicating investor confidence in their potential to impact cancer treatment significantly.

24. Arsenal Biosciences, Inc.

• Website: arsenalbio.com
• Ownership type: Venture Capital
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series C, $325.0M, September 2024
• Founded year: 2019
• Headcount: 201-500
• LinkedIn: aresnalbio

Arsenal Biosciences, Inc. is a biotechnology firm based in South San Francisco, California, founded in 2019. The company specializes in developing programmable cell therapies aimed at treating solid tumors, a challenging area in cancer treatment. With a team of experts from various scientific disciplines, ArsenalBio is dedicated to creating innovative solutions that improve patient outcomes. Their recent funding of $325 million in September 2024 highlights their growth potential and commitment to advancing their clinical programs. Arsenal Biosciences is actively engaged in the cell therapy industry, focusing on engineering medicines that can effectively tackle the complexities of cancer.

Cell Therapy Insights: Key Companies

Company	Headquarter	Size	Founded	Ownership
Kite Pharma	Santa Monica, California, United States (USA)	1001-5000	2009	Corporate
Dendreon	Seal Beach, California, United States (USA)	501-1000	1992	Corporate
Juventas Cell Therapy Corp.	Tianjin, Tianjin, China	51-200	2018	Private Equity
BlueRock Therapeutics	Cambridge, Massachusetts, United States (USA)	201-500	2016	Venture Capital
Curocell	Daejeon, Daejeon, South Korea	51-200	2016	Private Equity
Miltenyi Biomedicine	Bergisch Gladbach, North Rhine-Westphalia, Germany	51-200	2019	Private
AvenCell	Cambridge, Massachusetts, United States (USA)	51-200	2021	Private Equity
Beike Biotechnology Co., Ltd.	Shenzhen, Guangdong, China	201-500	2005	Private
ImmunoACT	Navi Mumbai, Maharashtra, India	51-200	2018	Private
Interius BioTherapeutics	Philadelphia, Pennsylvania, United States (USA)	11-50	2019	Venture Capital
Inceptor Bio	Morrisville, North Carolina, United States (USA)	11-50	2020	Corporate
MedTherapy Biotech	Quincy, Massachusetts, United States (USA)	11-50	2018	Private
Ferring Ventures Oy	Kuopio, North Savo, Finland	11-50	2018	Private
Orca Bio	Menlo Park, California, United States (USA)	51-200	2016	Venture Capital
Wugen	St. Louis, Missouri, United States (USA)	51-200	2018	Private Equity
Carina Biotech	Adelaide, South Australia, Australia	1-10	2016	Venture Capital
Ensoma	Boston, Massachusetts, United States (USA)	51-200	2019	Private Equity
PsiOxus	Abingdon, England, United Kingdom (UK)	51-200	2010	Private Equity
CytoImmune Therapeutics	Monrovia, California, United States (USA)	51-200	2019	Private
Appia Bio	Los Angeles, California, United States (USA)	11-50	2020	Venture Capital
TCRCure Biopharma Corp.	Guangzhou, Guangdong, China	51-200	2016	Private
BioSyngen	Singapore, Singapore	51-200	2016	Venture Capital
Leucid Bio	London, England, United Kingdom (UK)	11-50	2014	Venture Capital
Arsenal Biosciences, Inc.	South San Francisco, California, United States (USA)	201-500	2019	Venture Capital

Want to Find More Cell Therapy Companies?

If you want to find more companies that offer innovative therapies, particularly targeting cancer treatment and regenerative medicine you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!